Pneumonia News and Research RSS Feed - Pneumonia News and Research

Pneumonia is a leading cause of death and hospitalization, costing health care systems billions of dollars and an estimated 600,000 adult deaths worldwide each year. Pneumococcal disease is caused by the bacterium Streptococcus pneumoniae and the term describes a group of illnesses, including invasive infections, such as bacteremia/sepsis and meningitis, as well as pneumonia and upper respiratory tract infections. Although all age groups may be affected, the highest rate of pneumococcal disease occurs in young children and older adults. In addition, persons suffering from a wide range of chronic conditions (eg, diabetes, cardiovascular disease) and immune deficiencies are at increased risk.
FDA approves Allergan's sNDA to update label for TEFLARO (ceftaroline fosamil)

FDA approves Allergan's sNDA to update label for TEFLARO (ceftaroline fosamil)

Allergan plc today announced the U.S. Food and Drug Administration has approved the company's supplemental new drug application (sNDA) to update the label for TEFLARO (ceftaroline fosamil) for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP). [More]
Volatile anesthetics may combat viral and bacterial infections in the lung

Volatile anesthetics may combat viral and bacterial infections in the lung

In use for more than a century, inhaled anesthetics like nitrous oxide and halothane have made modern surgery possible. Now, in experiments in mice, researchers at Johns Hopkins and elsewhere have added to evidence that certain so-called "volatile" anesthetics -- commonly used during surgeries -- may also possess powerful effects on the immune system that can combat viral and bacterial infections in the lung, including influenza and pneumonia. [More]
Nektar receives $40 million cash payment from first commercial sale of MOVENTIG (naloxegol)

Nektar receives $40 million cash payment from first commercial sale of MOVENTIG (naloxegol)

Nektar Therapeutics announced today that it has received a $40 million cash payment under a license agreement with AstraZeneca. The payment was triggered by the first commercial sale of MOVENTIG (naloxegol) in Germany. [More]
Breakthrough antibody therapy shows significant promise against drug-resistant multiple myeloma

Breakthrough antibody therapy shows significant promise against drug-resistant multiple myeloma

In its first clinical trial, a breakthrough antibody therapy produced at least partial remissions in a third of patients with multiple myeloma who had exhausted multiple prior treatments, investigators at Dana-Farber Cancer Institute and other organizations report today online in the New England Journal of Medicine. [More]
FDA, EMA accept filing applications for Boehringer Ingelheim's afatinib to treat patients with advanced SCC of the lung

FDA, EMA accept filing applications for Boehringer Ingelheim's afatinib to treat patients with advanced SCC of the lung

Boehringer Ingelheim today announced that both the U.S. Food and Drug Administration and the European Medicines Agency have accepted filing applications for afatinib for the treatment of patients with advanced squamous cell carcinoma (SCC) of the lung progressing after treatment with first-line chemotherapy. [More]
Experimental MERS-CoV vaccine shows promise in monkeys and camels

Experimental MERS-CoV vaccine shows promise in monkeys and camels

National Institutes of Health scientists and colleagues report that an experimental vaccine given six weeks before exposure to Middle East respiratory syndrome coronavirus (MERS-CoV) fully protects rhesus macaques from disease. The vaccine also generated potentially protective MERS-CoV antibodies in blood drawn from vaccinated camels. [More]
Early exposure to inflammatory cytokines can paralyze CD4 T cells

Early exposure to inflammatory cytokines can paralyze CD4 T cells

In a discovery that is likely to rewrite immunology text books, researchers at UC Davis have found that early exposure to inflammatory cytokines, such as interleukin 2, can "paralyze" CD4 T cells, immune components that help orchestrate the body's response to pathogens and other invaders. [More]
Patient satisfaction a poor proxy for quality of care in elective cranial neurosurgery

Patient satisfaction a poor proxy for quality of care in elective cranial neurosurgery

Patient satisfaction is a very poor proxy for quality of care comparisons in elective cranial neurosurgery. Because deaths are rare events in elective cranial neurosurgery, reporting of surgeon or even department-specific mortality figures cannot differentiate a high or low level of the quality of care. [More]
U-M microbiome research may lead to new ways to prevent, fight lung infections in patients

U-M microbiome research may lead to new ways to prevent, fight lung infections in patients

With every breath you take, microbes have a chance of making it into your lungs. But what happens when they get there? And why do dangerous lung infections like pneumonia happen in some people, but not others? Researchers at the University of Michigan Medical School have started to answer these questions by studying the microbiome of the lungs - the community of microscopic organisms that are in constant contact with our respiratory system. [More]
Breastfeeding may lead to substantial reduction in common infections among Indigenous babies

Breastfeeding may lead to substantial reduction in common infections among Indigenous babies

Promoting breastfeeding could lead to a substantial reduction in common infections and even deaths that are more common in Indigenous infants than non-Indigenous infants, a new study suggests. [More]
Psychological disorders in COPD patients predict early hospital readmission

Psychological disorders in COPD patients predict early hospital readmission

Researchers from The University of Texas Medical Branch at Galveston found that people with a psychological condition such as depression, anxiety, psychosis, or alcohol/drug abuse are more likely to be readmitted early into a hospital for complications of chronic obstructive pulmonary disease. [More]
McMaster research shows benefits of corticosteroid therapy for patients with pneumonia

McMaster research shows benefits of corticosteroid therapy for patients with pneumonia

McMaster University research, published online today by the Annals of Internal Medicine, has demonstrated the benefits of corticosteroid therapy for one of the most common serious medical conditions. [More]
Hospital physicians rarely identify or address overweight/obesity in children

Hospital physicians rarely identify or address overweight/obesity in children

Physicians and physician trainees fail to identify or address overweight/obesity in over 90 percent of hospitalized children, according to new research from a Saint Louis University pediatric hospitalist. [More]
Coordinated, two-part approach could help reduce hospital-acquired infections

Coordinated, two-part approach could help reduce hospital-acquired infections

By coordinating with state health departments and communicating with each other about patients with C. difficile and antibiotic-resistant infections, hospitals, long-term acute-care facilities and nursing homes could reduce the number of such hospital-acquired infections (HAIs) by an estimated 619,000 cases in the next five years, a new Centers for Disease Control 9 (CDC)-led report has found. [More]
California Initiative to Advance Precision Medicine selects two demonstration projects

California Initiative to Advance Precision Medicine selects two demonstration projects

Two demonstration projects that aim to yield quick results for patients have been selected by the new California Initiative to Advance Precision Medicine, a public-private effort launched by Governor Edmund G. Brown Jr. [More]
Vaccine containing virus-like nanoparticles could be novel treatment option for RSV

Vaccine containing virus-like nanoparticles could be novel treatment option for RSV

A vaccine containing virus-like nanoparticles, or microscopic, genetically engineered particles, is an effective treatment for respiratory syncytial virus (RSV), according to researchers at Georgia State University. [More]
Study shows link between liver-produced molecules, pneumonia susceptibility during sepsis

Study shows link between liver-produced molecules, pneumonia susceptibility during sepsis

New evidence highlights the importance of the liver in immunity against bacterial pneumonia. The study is the first of its kind to directly show such a link between liver-produced molecules and pneumonia susceptibility during sepsis. [More]
Hospitals penalized in HAC Reduction program may not reflect poor quality of care, shows study

Hospitals penalized in HAC Reduction program may not reflect poor quality of care, shows study

Hospitals that were penalized more frequently in the Hospital-Acquired Condition (HAC) Reduction Program offered advanced services, were major teaching institutions and had better performance on other publicly reported process-of-care and outcome measures, according to a study in the July 28 issue of JAMA, a theme issue on Medicare and Medicaid at 50. [More]
New white paper provides overview of factors that drive vaccination underutilization in older adults

New white paper provides overview of factors that drive vaccination underutilization in older adults

Today the nonprofit Alliance for Aging Research released a white paper, Our Best Shot: Expanding Prevention through Vaccination in Older Adults, that provides a comprehensive overview of the factors that drive vaccination underutilization in seniors and offers recommendations on how industry, government, and health care experts can improve patient compliance. [More]
Researchers uncover groundbreaking evidence for developing vaccine to prevent middle ear infections

Researchers uncover groundbreaking evidence for developing vaccine to prevent middle ear infections

Researchers from Griffith University's Institute for Glycomics, together with the Nationwide Children's Hospital in Ohio, have uncovered groundbreaking evidence to help vaccine developers prevent middle ear infections. [More]
Advertisement
Advertisement